Loading company…
Transcripta Bio uses transcriptome-scale analysis to discover and assess potential drug candidates.
Transcripta Bio combines a screening platform and Conductor AI predictive model to study drug effects across the cell transcriptome and identify therapeutic candidates. Founded in 2020 by Chris Moxham and Onno Faber, the company is based in California, US. In July 2026, it raised USD 24 million in Series A funding from Mayo Clinic Ventures, Omnimed Capital, JAZZ Venture Partners, and BlueYard Capital to support IND-enabling studies and clinical preparation for its autism spectrum disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD) programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in